Managing Comorbidities and Mitigating Atopic March in Adolescent and Adult Patients

EP: 1.Overview of Atopic Dermatitis Pathophysiology and Atopic March in Children

EP: 2.Considerations for Diagnosing Atopic Dermatitis and Assessing Severity

EP: 3.Exploring the Pediatric Patient and Caregiver Journey

EP: 4.Multidisciplinary Approaches to Atopic Dermatitis Management and Referrals

EP: 5.Setting Goals for Pediatric Atopic Dermatitis Treatment

EP: 6.Real-World Challenges to Providing Evidence-Based Care for Atopic Dermatitis

EP: 7.Navigating New Treatment Options for Pediatric Atopic Dermatitis Management

Now Viewing

EP: 8.Managing Comorbidities and Mitigating Atopic March in Adolescent and Adult Patients

EP: 9.Expectations for Efficacy and Duration of Response With Systemic Atopic Dermatitis Treatments

EP: 10.Considerations for Switching Systemic Agents in Atopic Dermatitis

EP: 11.Future Directions in the Treatment of Pediatric Atopic Dermatitis

EP: 12.Patient and Caregiver Advice for Navigating Atopic Dermatitis

EP: 13.Key Takeaways on the Evolving Landscape of Pediatric Atopic Dermatitis Treatment

Video content above is prompted by the following:

• How do the treatment options evolve as a child ages?
• FDA labeling (dupilumab ≥ 6 months, lebrikizumab ≥ 12 years, tralokinumab ≥ 12 years, abrocitinib ≥ 12 years, upadacitinib ≥ 12 years) vs off-label use
• How can the use of these systemic agents in pediatric patients potentially mitigate the atopic march? What can we do to halt the progression of pediatric atopic diseases?
• Lin 2024: A cohort taking dupilumab showed a significant risk reduction in atopic march (HR, 0.60 for developing asthma; HR, 0.69 for developing allergic rhinitis) in patients 18 years or younger vs conventional immunomodulatory care without dupilumab.